Skip to content
Citalopram
Celexa (citalopram) is a small molecule pharmaceutical. Citalopram was first approved as Celexa on 1998-07-17. It is used to treat alcoholism, dementia, depressive disorder, diabetic neuropathies, and obsessive-compulsive disorder amongst others in the USA. The pharmaceutical is active against sodium-dependent serotonin transporter. In addition, it is known to target sodium-dependent noradrenaline transporter.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
endocrine system diseasesD004700
chemically-induced disordersD064419
mental disordersD001523
Trade Name
FDA
EMA
Celexa (generic drugs available since 2004-10-28)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Citalopram hydrobromide
Tradename
Company
Number
Date
Products
CELEXAAbbVieN-020822 RX1998-07-17
3 products, RLD, RS
CITALOPRAM HYDROBROMIDEAlmatica PharmaN-215428 RX2022-01-31
1 products, RLD, RS
Show 3 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
celexaNew Drug Application2022-02-08
citalopram hydrobromideANDA2023-06-13
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
alcoholismEFO_0003829D000437F10.1
dementiaHP_0000726D003704F03
depressive disorderEFO_1002014D003866F32.A
diabetic neuropathiesEFO_1000783D003929—
obsessive-compulsive disorderEFO_0004242D009771F42
tobacco use disorder—D014029F17
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N06: Psychoanaleptics
— N06A: Antidepressants
— N06AB: Selective serotonin reuptake inhibitors
— N06AB04: Citalopram
HCPCS
No data
Clinical
Clinical Trials
4 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GastroparesisD018589EFO_1000948K31.84———2—2
Diabetes mellitusD003920EFO_0000400E08-E13———1—1
Gastroesophageal refluxD005764EFO_0003948K21———1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCITALOPRAM
INNcitalopram
Description
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile is a nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group. It is a member of 2-benzofurans, a nitrile, an organofluorine compound, a cyclic ether and a tertiary amino compound. It is a conjugate base of a 3-[5-cyano-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-1-yl]-N,N-dimethylpropan-1-aminium.
Classification
Small molecule
Drug classSelective serotonin reuptake inhibitor (SSRI)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
Identifiers
PDB—
CAS-ID59729-33-8
RxCUI—
ChEMBL IDCHEMBL549
ChEBI ID77397
PubChem CID2771
DrugBankDB00215
UNII ID0DHU5B8D6V (ChemIDplus, GSRS)
Target
Agency Approved
SLC6A4
SLC6A4
Organism
Homo sapiens
Gene name
SLC6A4
Gene synonyms
HTT, SERT
NCBI Gene ID
6532
Protein name
sodium-dependent serotonin transporter
Protein synonyms
5-hydroxytryptamine (serotonin) transporter, 5HT transporter, 5HTT, Na+/Cl- dependent serotonin transporter, serotonin transporter 1, solute carrier family 6 (neurotransmitter transporter), member 4, solute carrier family 6 (neurotransmitter transporter, serotonin), member 4, Solute carrier family 6 member 4
Uniprot ID
Q5EE02
Mouse ortholog
Slc6a4 (15567)
sodium-dependent serotonin transporter (Q60857)
Alternate
SLC6A2
SLC6A2
Organism
Homo sapiens
Gene name
SLC6A2
Gene synonyms
NAT1, NET1, SLC6A5
NCBI Gene ID
6530
Protein name
sodium-dependent noradrenaline transporter
Protein synonyms
NET, neurotransmitter transporter, Norepinephrine transporter, solute carrier family 6 (neurotransmitter transporter), member 2, solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2, Solute carrier family 6 member 2, solute carrier family 6 member 5
Uniprot ID
Q96KH8
Mouse ortholog
Slc6a2 (20538)
sodium-dependent noradrenaline transporter (Q6QU62)
Variants
Clinical Variant
Identifier
Target mutation
Effect
Evaluation
Status
VCV000638805CYP2C19, Gly91Argdrug response2019-06-17P
VCV000638804CYP2C19, His78Tyrdrug response2019-06-17P
VCV000638803CYP2C19, Arg73Cysdrug response2019-06-17P
VCV000638802CYP2C19, Arg442Cysdrug response2019-06-17P
VCV000638801CYP2C19, Ser51Glydrug response2019-06-17P
VCV000638800CYP2C19, Asp256Asndrug response2019-06-17P
VCV000638799CYP2C19, Ile19Leudrug response2019-06-17P
VCV000638798CYP2C19, Arg335Gln, Lys399=drug response2019-06-17P
VCV000638797CYP2C19, Pro227=drug response2019-06-17P
VCV000638796CYP2C19, Arg410Cysdrug response2019-06-17P
Show 585 more
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 18,846 documents
View more details
Safety
Black-box Warning
Black-box warning for: Celexa, Citalopram hydrobromide
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,334 adverse events reported
View more details